Gilead Sciences, Inc. vs Manchester United PLC — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Manchester United PLC trades at $22.23 (market cap $3.80B). The key difference: Gilead Sciences, Inc. is far larger — about 44.3× Manchester United PLC's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MANU | |
|---|---|---|
Market Cap | $168.35B | $3.80B |
Sector | Health | Media |
52-Week High | $155.80 | $23.53 |
52-Week Low | $110.56 | $15.10 |
Enterprise Value | $191.42B | $4.74B |
Dividend Yield | 2.42% | 1.26% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →